Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Clovis Oncology Inc (CLVS)

Clovis Oncology Inc (CLVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 530,797
  • Shares Outstanding, K 88,319
  • Annual Sales, $ 143,010 K
  • Annual Income, $ -400,420 K
  • 60-Month Beta 1.78
  • Price/Sales 2.76
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CLVS with:

Options Overview

Details
  • Implied Volatility 110.80%
  • Historical Volatility 108.86%
  • IV Percentile 67%
  • IV Rank 13.85%
  • IV High 438.73% on 03/12/20
  • IV Low 58.06% on 11/25/20
  • Put/Call Vol Ratio 0.46
  • Today's Volume 2,603
  • Volume Avg (30-Day) 20,292
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 84,370
  • Open Int (30-Day) 113,622

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.76
  • Number of Estimates 5
  • High Estimate -0.62
  • Low Estimate -0.85
  • Prior Year -1.81
  • Growth Rate Est. (year over year) +58.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.75 +6.35%
on 02/23/21
11.10 -44.91%
on 02/08/21
-0.57 (-8.46%)
since 01/22/21
3-Month
4.35 +40.57%
on 11/25/20
11.10 -44.91%
on 02/08/21
+1.72 (+39.29%)
since 11/24/20
52-Week
3.62 +68.92%
on 03/17/20
11.10 -44.91%
on 02/08/21
-3.81 (-38.36%)
since 02/24/20

Most Recent Stories

More News
Clovis (CLVS) Q4 Earnings Miss, Revenues Beat, Stock Down

Clovis (CLVS) reports wider-than-expected loss for fourth-quarter 2020. Sales of the company's sole marketed drug, Rubraca, increase year over year.

MRNA : 145.88 (-2.86%)
BMY : 62.84 (+3.49%)
LXRX : 7.93 (+6.59%)
CLVS : 6.08 (+1.16%)
Extensive Demand for T-Cell Adoptive Immunotherapy Rising with Growing Prevalence of Cancer

PALM BEACH,  Fla., /PRNewswire/ -- In the breast cancer therapy market, the rise in the prevalence of cancer, has propelled the T-cell therapy market over the last few years and it is projected to continue...

ONCY : 3.80 (+1.88%)
ONC.TO : 4.73 (+1.50%)
VCNX : 4.26 (+6.77%)
PDSB : 4.94 (+4.88%)
CTXR : 2.35 (+0.43%)
CLVS : 6.08 (+1.16%)
Clovis: 4Q Earnings Snapshot

BOULDER, Colo. (AP) _ Clovis Oncology Inc. (CLVS) on Tuesday reported a loss of $99 million in its fourth quarter.

CLVS : 6.08 (+1.16%)
Clovis Oncology Announces 2020 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2020, and provided an update on the Company's clinical development programs and regulatory and...

CLVS : 6.08 (+1.16%)
Clovis Oncology, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 23, 2021 / Clovis Oncology, Inc. (NASDAQ:CLVS) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 23, 2021...

CLVS : 6.08 (+1.16%)
Clovis Oncology to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Webcast Conference Call on February 23

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and year-end 2020 financial results on Tuesday, February 23, 2021, before the open of the U.S. financial markets. Clovis' senior management...

CLVS : 6.08 (+1.16%)
Clovis Oncology Presents Data in Advanced Prostate Cancer at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced Rubraca data being presented at the American Society for Clinical Oncology (ASCO) Genitourinary Cancers Virtual Symposium 2021. These include data from...

CLVS : 6.08 (+1.16%)
Uptrend Call Working As Clovis Oncology Stock Rises 81.7% (CLVS)

SmarTrend identified an Uptrend for Clovis Oncology (NASDAQ:CLVS) on January 11th, 2021 at $5.42. In approximately 1 month, Clovis Oncology has returned 81.73% as of today's recent price of $9.85.

CLVS : 6.08 (+1.16%)
New Study from Foundation Medicine and Collaborators Further Demonstrates the Clinical Utility of Blood-Based Comprehensive Genomic Profiling in Patients with Advanced Prostate Cancer

Foundation Medicine, Inc. and its collaborators today announced results from a prostate cancer study evaluating the landscape of genomic alterations identified by liquid biopsy in over 3,000 patients,...

CLVS : 6.08 (+1.16%)
FMI : 136.95 (-0.04%)
Clovis Oncology to Highlight Data at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting

Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that two abstracts featuring data from clinical studies evaluating Rubraca(R) (rucaparib) in metastatic castration-resistant prostate cancer (mCRPC)...

CLVS : 6.08 (+1.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations....

See More

Key Turning Points

3rd Resistance Point 7.17
2nd Resistance Point 6.84
1st Resistance Point 6.42
Last Price 6.08
1st Support Level 5.67
2nd Support Level 5.34
3rd Support Level 4.92

See More

52-Week High 11.10
Fibonacci 61.8% 8.24
Fibonacci 50% 7.36
Fibonacci 38.2% 6.48
Last Price 6.08
52-Week Low 3.62

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar